Matches in SemOpenAlex for { <https://semopenalex.org/work/W2128580651> ?p ?o ?g. }
- W2128580651 endingPage "270" @default.
- W2128580651 startingPage "262" @default.
- W2128580651 abstract "BackgroundWhile producing good-quality analgesia, µ-opioid (MOP) receptor activation produces a number of side-effects including tolerance. Simultaneous blockade of δ-opioid (DOP) receptors has been shown to reduce tolerance to morphine. Here, we characterize a prototype bifunctional opioid H-Dmt-Tic-Gly-NH-Bzl (UFP-505).MethodsWe measured receptor binding affinity in Chinese hamster ovary (CHO) cells expressing recombinant human MOP, DOP, k-opioid (KOP), nociceptin/orphanin (NOP) receptors. For activation, we measured the binding of GTPγ35S to membranes from CHOhMOP, CHOhDOP, rat cerebrocortex, and rat spinal cord. In addition, we assessed ‘end organ’ responses in the guinea pig ileum and mouse vas deferens.ResultsUFP-505 bound to CHOhMOP and CHOhDOP with (binding affinity) pKi values of 7.79 and 9.82, respectively. There was a weak interaction at KOP and NOP (pKi 6.29 and 5.86). At CHOhMOP, UFP-505 stimulated GTPγ35S binding with potency (pEC50) of 6.37 and in CHOhDOP reversed the effects of a DOP agonist with affinity (pKb) of 9.81 (in agreement with pKi at DOP). UFP-505 also stimulated GTPγ35S binding in rat cerebrocortex and spinal cord with pEC50 values of 6.11–6.53. In the guinea pig ileum (MOP-rich preparation), UFP-505 inhibited contractility with pEC50 of 7.50 and in the vas deferens (DOP-rich preparation) reversed the effects of a DOP agonist with an affinity (pA2) of 9.15.ConclusionsWe have shown in a range of preparations and assays that UFP-505 behaves as a potent MOP agonist and DOP antagonist; a MOP/DOP bifunctional opioid. Further studies in dual expression systems and whole animals with this prototype are warranted. While producing good-quality analgesia, µ-opioid (MOP) receptor activation produces a number of side-effects including tolerance. Simultaneous blockade of δ-opioid (DOP) receptors has been shown to reduce tolerance to morphine. Here, we characterize a prototype bifunctional opioid H-Dmt-Tic-Gly-NH-Bzl (UFP-505). We measured receptor binding affinity in Chinese hamster ovary (CHO) cells expressing recombinant human MOP, DOP, k-opioid (KOP), nociceptin/orphanin (NOP) receptors. For activation, we measured the binding of GTPγ35S to membranes from CHOhMOP, CHOhDOP, rat cerebrocortex, and rat spinal cord. In addition, we assessed ‘end organ’ responses in the guinea pig ileum and mouse vas deferens. UFP-505 bound to CHOhMOP and CHOhDOP with (binding affinity) pKi values of 7.79 and 9.82, respectively. There was a weak interaction at KOP and NOP (pKi 6.29 and 5.86). At CHOhMOP, UFP-505 stimulated GTPγ35S binding with potency (pEC50) of 6.37 and in CHOhDOP reversed the effects of a DOP agonist with affinity (pKb) of 9.81 (in agreement with pKi at DOP). UFP-505 also stimulated GTPγ35S binding in rat cerebrocortex and spinal cord with pEC50 values of 6.11–6.53. In the guinea pig ileum (MOP-rich preparation), UFP-505 inhibited contractility with pEC50 of 7.50 and in the vas deferens (DOP-rich preparation) reversed the effects of a DOP agonist with an affinity (pA2) of 9.15. We have shown in a range of preparations and assays that UFP-505 behaves as a potent MOP agonist and DOP antagonist; a MOP/DOP bifunctional opioid. Further studies in dual expression systems and whole animals with this prototype are warranted." @default.
- W2128580651 created "2016-06-24" @default.
- W2128580651 creator A5028341235 @default.
- W2128580651 creator A5030826985 @default.
- W2128580651 creator A5044328039 @default.
- W2128580651 creator A5049357305 @default.
- W2128580651 creator A5056696512 @default.
- W2128580651 creator A5061719307 @default.
- W2128580651 creator A5063933209 @default.
- W2128580651 date "2012-02-01" @default.
- W2128580651 modified "2023-10-18" @default.
- W2128580651 title "Pharmacological characterization of the bifunctional opioid ligand H-Dmt-Tic-Gly-NH-Bzl (UFP-505) †" @default.
- W2128580651 cites W1601461368 @default.
- W2128580651 cites W1965333793 @default.
- W2128580651 cites W1965534248 @default.
- W2128580651 cites W1982943198 @default.
- W2128580651 cites W1984551968 @default.
- W2128580651 cites W1992961161 @default.
- W2128580651 cites W1996214244 @default.
- W2128580651 cites W1997650254 @default.
- W2128580651 cites W1997675350 @default.
- W2128580651 cites W2000176929 @default.
- W2128580651 cites W2008504276 @default.
- W2128580651 cites W2010051841 @default.
- W2128580651 cites W2012998083 @default.
- W2128580651 cites W2014598698 @default.
- W2128580651 cites W2015173581 @default.
- W2128580651 cites W2017860510 @default.
- W2128580651 cites W2019328492 @default.
- W2128580651 cites W2030333682 @default.
- W2128580651 cites W2032005626 @default.
- W2128580651 cites W2048130564 @default.
- W2128580651 cites W2049601255 @default.
- W2128580651 cites W2063083641 @default.
- W2128580651 cites W2074631079 @default.
- W2128580651 cites W2077214024 @default.
- W2128580651 cites W2079852966 @default.
- W2128580651 cites W2079946171 @default.
- W2128580651 cites W2086327881 @default.
- W2128580651 cites W2091993879 @default.
- W2128580651 cites W2094109627 @default.
- W2128580651 cites W2096002902 @default.
- W2128580651 cites W2105114041 @default.
- W2128580651 cites W2107152627 @default.
- W2128580651 cites W2126523488 @default.
- W2128580651 cites W2137736823 @default.
- W2128580651 cites W2143379226 @default.
- W2128580651 cites W2165004472 @default.
- W2128580651 cites W2167385805 @default.
- W2128580651 cites W2169996576 @default.
- W2128580651 cites W2171509007 @default.
- W2128580651 cites W2172120804 @default.
- W2128580651 cites W4254848357 @default.
- W2128580651 cites W4297627434 @default.
- W2128580651 doi "https://doi.org/10.1093/bja/aer377" @default.
- W2128580651 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22194444" @default.
- W2128580651 hasPublicationYear "2012" @default.
- W2128580651 type Work @default.
- W2128580651 sameAs 2128580651 @default.
- W2128580651 citedByCount "13" @default.
- W2128580651 countsByYear W21285806512012 @default.
- W2128580651 countsByYear W21285806512013 @default.
- W2128580651 countsByYear W21285806512015 @default.
- W2128580651 countsByYear W21285806512016 @default.
- W2128580651 countsByYear W21285806512018 @default.
- W2128580651 countsByYear W21285806512019 @default.
- W2128580651 countsByYear W21285806512020 @default.
- W2128580651 countsByYear W21285806512022 @default.
- W2128580651 crossrefType "journal-article" @default.
- W2128580651 hasAuthorship W2128580651A5028341235 @default.
- W2128580651 hasAuthorship W2128580651A5030826985 @default.
- W2128580651 hasAuthorship W2128580651A5044328039 @default.
- W2128580651 hasAuthorship W2128580651A5049357305 @default.
- W2128580651 hasAuthorship W2128580651A5056696512 @default.
- W2128580651 hasAuthorship W2128580651A5061719307 @default.
- W2128580651 hasAuthorship W2128580651A5063933209 @default.
- W2128580651 hasBestOaLocation W21285806511 @default.
- W2128580651 hasConcept C125439840 @default.
- W2128580651 hasConcept C126322002 @default.
- W2128580651 hasConcept C159023312 @default.
- W2128580651 hasConcept C170493617 @default.
- W2128580651 hasConcept C175656101 @default.
- W2128580651 hasConcept C185592680 @default.
- W2128580651 hasConcept C2778938600 @default.
- W2128580651 hasConcept C2781063702 @default.
- W2128580651 hasConcept C55493867 @default.
- W2128580651 hasConcept C58732023 @default.
- W2128580651 hasConcept C71924100 @default.
- W2128580651 hasConcept C86803240 @default.
- W2128580651 hasConcept C88016717 @default.
- W2128580651 hasConcept C98274493 @default.
- W2128580651 hasConceptScore W2128580651C125439840 @default.
- W2128580651 hasConceptScore W2128580651C126322002 @default.
- W2128580651 hasConceptScore W2128580651C159023312 @default.
- W2128580651 hasConceptScore W2128580651C170493617 @default.
- W2128580651 hasConceptScore W2128580651C175656101 @default.
- W2128580651 hasConceptScore W2128580651C185592680 @default.
- W2128580651 hasConceptScore W2128580651C2778938600 @default.